(Q44340798)

2 December 2017

title

Opioid effects and opioid withdrawal during a 24 h dosing interval in patients maintained on buprenorphine (English)

1 reference

2 December 2017

0 references

2

1 reference

2 December 2017

Olga V Lopatko

1

1 reference

2 December 2017

Alice Huber

series ordinal

3

1 reference

2 December 2017

Walter Ling

series ordinal

4

1 reference

2 December 2017

publication date

1 April 2003

1 reference

Drug and Alcohol Dependence

2 December 2017

published in

1 reference

2 December 2017

volume

69

1 reference

2 December 2017

issue

3

1 reference

2 December 2017

page(s)

317-322

1 reference

Buprenorphine dosing every 1, 2, or 3 days in opioid-dependent patients

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2802%2900322-8

7 January 2021

Buprenorphine kinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2802%2900322-8

7 January 2021

Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: Comparison of those who do and do not experience withdrawal and concentration-effect relationships

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2802%2900322-8

7 January 2021

The relationship between mood state and plasma methadone concentration in maintenance patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2802%2900322-8

7 January 2021

Naloxone reversal of buprenorphine-induced respiratory depression

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2802%2900322-8

7 January 2021

Buprenorphine: a review of its pharmacological properties and therapeutic efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2802%2900322-8

7 January 2021

Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2802%2900322-8

7 January 2021

A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2802%2900322-8

7 January 2021

Short-term effects of oral methadone in methadone maintenance subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2802%2900322-8

7 January 2021

Clinical effects of buprenorphine during and after operation

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2802%2900322-8

7 January 2021

Determination of buprenorphine in human plasma by gas chromatography-positive ion chemical ionization mass spectrometry and liquid chromatography-tandem mass spectrometry.

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2802%2900322-8

7 January 2021

A comparison of four buprenorphine dosing regimens in the treatment of opioid dependence

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2802%2900322-8

7 January 2021

A comparison of four buprenorphine dosing regimens using open-dosing procedures: is twice-weekly dosing possible?

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2802%2900322-8

7 January 2021

Onset, magnitude and duration of opioid blockade produced by buprenorphine and naltrexone in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2802%2900322-8

7 January 2021

Clinical pharmacology of buprenorphine: ceiling effects at high doses

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2802%2900322-8

7 January 2021

10.1016/S0376-8716(02)00322-8

Identifiers

DOI

1 reference

2 December 2017

1 reference